immunologic factors

Summary

Summary: Biologically active substances whose activities affect or play a role in the functioning of the immune system.

Top Publications

  1. doi Systemic lupus erythematosus
    Anisur Rahman
    Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
    N Engl J Med 358:929-39. 2008
  2. ncbi B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
    Stephen L Hauser
    Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0114, USA
    N Engl J Med 358:676-88. 2008
  3. ncbi Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells
    Mauro Krampera
    Department of Clinical and Experimental Medicine, University of Verona, Italy
    Stem Cells 24:386-98. 2006
  4. ncbi Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    Joan T Merrill
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Arthritis Rheum 62:222-33. 2010
  5. ncbi Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
    Sandra V Navarra
    University of Santo Tomas Hospital, Manila, Philippines
    Lancet 377:721-31. 2011
  6. ncbi Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
    David B Clifford
    Department of Neurology, Washington University in St Louis, Saint Louis, MO 63110, USA
    Lancet Neurol 9:438-46. 2010
  7. pmc Deconstructing tick saliva: non-protein molecules with potent immunomodulatory properties
    Carlo José F Oliveira
    Department of Biochemistry and Immunology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    J Biol Chem 286:10960-9. 2011
  8. ncbi Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    Christopher E M Griffiths
    University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
    N Engl J Med 362:118-28. 2010
  9. ncbi Helminth-derived immunomodulators: can understanding the worm produce the pill?
    William Harnett
    Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
    Nat Rev Immunol 10:278-84. 2010
  10. pmc Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids
    Corinne Grangette
    Laboratoire de Bactériologie des Ecosytèmes, Institut Pasteur de Lille Institut de Biologie de Lille, 59019 Lille Cedex, France
    Proc Natl Acad Sci U S A 102:10321-6. 2005

Research Grants

Detail Information

Publications347 found, 100 shown here

  1. doi Systemic lupus erythematosus
    Anisur Rahman
    Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
    N Engl J Med 358:929-39. 2008
  2. ncbi B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
    Stephen L Hauser
    Department of Neurology, University of California at San Francisco, San Francisco, CA 94143 0114, USA
    N Engl J Med 358:676-88. 2008
    ..There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes...
  3. ncbi Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells
    Mauro Krampera
    Department of Clinical and Experimental Medicine, University of Verona, Italy
    Stem Cells 24:386-98. 2006
    ..These findings suggest that the beneficial effect on graft-versus-host disease induced by in vivo coinfusion with the graft of MSCs may be due to the activation of the immunomodulatory properties of MSCs by T cell- derived IFN-gamma...
  4. ncbi Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
    Joan T Merrill
    Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Arthritis Rheum 62:222-33. 2010
    ..The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately-to-severely active extrarenal SLE...
  5. ncbi Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
    Sandra V Navarra
    University of Santo Tomas Hospital, Manila, Philippines
    Lancet 377:721-31. 2011
    ..The efficacy and safety of the fully human monoclonal antibody belimumab (BLyS-specific inhibitor) was assessed in patients with active systemic lupus erythematosus...
  6. ncbi Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
    David B Clifford
    Department of Neurology, Washington University in St Louis, Saint Louis, MO 63110, USA
    Lancet Neurol 9:438-46. 2010
    ..Assessment of these clinical cases will help to inform future therapeutic judgments and improve the outcomes for patients...
  7. pmc Deconstructing tick saliva: non-protein molecules with potent immunomodulatory properties
    Carlo José F Oliveira
    Department of Biochemistry and Immunology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil
    J Biol Chem 286:10960-9. 2011
    ..The presence of non-protein molecules adenosine and PGE(2) in tick saliva indicates an important evolutionary mechanism used by ticks to subvert host immune cells and allow them to successfully complete their blood meal and life cycle...
  8. ncbi Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    Christopher E M Griffiths
    University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
    N Engl J Med 362:118-28. 2010
    ..We compared two biologic agents, ustekinumab (an interleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha), for the treatment of psoriasis...
  9. ncbi Helminth-derived immunomodulators: can understanding the worm produce the pill?
    William Harnett
    Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
    Nat Rev Immunol 10:278-84. 2010
    ....
  10. pmc Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids
    Corinne Grangette
    Laboratoire de Bactériologie des Ecosytèmes, Institut Pasteur de Lille Institut de Biologie de Lille, 59019 Lille Cedex, France
    Proc Natl Acad Sci U S A 102:10321-6. 2005
    ..The results indicated that composition of LTA within the whole-cell context of L. plantarum can modulate proinflammatory or antiinflammatory immune responses...
  11. ncbi Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
    Jt Merrill
    Oklahoma Medical Research Foundation, Oklahoma City 73104, USA
    Lupus 20:709-16. 2011
    ..204). This post hoc analysis evaluates the hypothesis that assessment of BILAG A flares may distinguish potential treatment effects with greater sensitivity than assessment of BILAG B flares...
  12. ncbi Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
    M Mehling
    Department of Neurology, University Hospitals Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Neurology 75:403-10. 2010
    ..In this study, we determined the phenotype and frequency of Th17 cells in blood of untreated, FTY720-treated, and interferon-beta (IFNbeta)-treated patients with MS and healthy donors...
  13. ncbi Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis
    Amal Ephrem
    Centre de Recherche des Cordeliers, Universite Pierre et Marie Curie Paris 6, UMR S 872, Inserm U872, France
    Blood 111:715-22. 2008
    ..In conclusion, our results highlight a novel mechanism of action of IVIg and provide a rationale to test the use of IVIg as an immunomodulatory tool to enhance Treg in early onset MS and other autoimmune and inflammatory conditions...
  14. ncbi Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
    Mark D Pescovitz
    Indiana University School of Medicine, Indianapolis, USA
    N Engl J Med 361:2143-52. 2009
    ..It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes...
  15. ncbi Human mesenchymal stem cells modulate allogeneic immune cell responses
    Sudeepta Aggarwal
    Osiris Therapeutics, 2001 Aliceanna St, Baltimore, MD 21231, USA
    Blood 105:1815-22. 2005
    ....
  16. ncbi B cell biomarkers of rituximab responses in systemic lupus erythematosus
    Edward M Vital
    University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    Arthritis Rheum 63:3038-47. 2011
    ....
  17. ncbi Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy
    Jennifer H Anolik
    University of Rochester, Rochester, New York 14642, USA
    Arthritis Rheum 56:3044-56. 2007
    ..This study was undertaken to determine the magnitude, duration, and cause of these defects in rituximab-treated systemic lupus erythematosus (SLE) patients...
  18. pmc Genomic analysis of the immune gene repertoire of amphioxus reveals extraordinary innate complexity and diversity
    Shengfeng Huang
    State Key Laboratory of Biocontrol, Guangdong Key Laboratory of Pharmaceutical Functional Genes, College of Life Sciences, Sun Yat Sen Zhongshan University, Guangzhou 510275, People s Republic of China
    Genome Res 18:1112-26. 2008
    ..Altogether, this survey suggests that the amphioxus, a species without vertebrate-type adaptive immunity, holds extraordinary innate complexity and diversity...
  19. ncbi New natural history of interferon-beta-treated relapsing multiple sclerosis
    Maria Trojano
    Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
    Ann Neurol 61:300-6. 2007
    ..To investigate the impact of interferon-beta (IFNbeta) on disease progression in relapsing-remitting multiple sclerosis patients...
  20. ncbi Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations
    H Wiendl
    Department of Neurology and Clinical Research, Unit for MS and Neuroimmunology, University of Wurzburg, Wurzburg, Germany
    J Neurol 255:1449-63. 2008
    ..The review also outlines a few areas of controversy and delineates the need for future research...
  21. pmc How vaccinia virus has evolved to subvert the host immune response
    Mohammad W Bahar
    Division of Structural Biology and Oxford Protein Production Facility, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX37BN, United Kingdom
    J Struct Biol 175:127-34. 2011
    ....
  22. ncbi A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages
    Corinna Schnoeller
    Department of Molecular Parasitology, Humboldt University, Berlin, Germany
    J Immunol 180:4265-72. 2008
    ..Our data demonstrate that treatment with a single helminth protein can exert the antiallergic effects of helminth infections...
  23. ncbi Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab
    Shigeru Iwata
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Yahata Nishi, Kitakyushu 807 8555, Japan
    J Rheumatol 38:633-41. 2011
    ..We investigated longitudinally the differentiation and phenotypic changes of peripheral B cells and T cells in patients with SLE after rituximab treatment...
  24. ncbi Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma
    Corrado Tarella
    Hematology and Cell Therapy, A O Mauriziano, Nuclear Medicine and Hematology, A O U S Giovanni B, Clinica Medica, A O U S Luigi Orbassano, University of TorinoTorino, Italy
    J Clin Oncol 29:814-24. 2011
    ..These issues have been addressed in a series of 1,347 patients with lymphoma treated with a high-dose sequential (HDS) program...
  25. pmc Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
    Alan G Ramsay
    Centre for Haemato Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
    Blood 120:1412-21. 2012
    ..These findings should contribute to the design of immunotherapeutic strategies to reverse T-cell tolerance in cancer...
  26. pmc Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
    Ronald F van Vollenhoven
    Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska Institute, Stockholm, Sweden
    Ann Rheum Dis 71:1343-9. 2012
    ..To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets...
  27. ncbi In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells
    E G Kamburova
    Department of Laboratory Medicine, Laboratory Medical Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Am J Transplant 12:341-50. 2012
    ..Overall, these results demonstrate that rituximab can affect human B-cell phenotype and function, resulting in an altered outcome of B-T cell interaction...
  28. ncbi Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease
    Gabriele Hörmannsperger
    Biofunctionality, ZIEL Research Center for Nutrition and Food Science, CDD Center for Diet and Disease, Technische Universitat Munchen, Am Forum 5, D 85350 Freising Weihenstephan, Germany
    Int J Med Microbiol 300:63-73. 2010
    ....
  29. pmc Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
    Alan G Ramsay
    Institute of Cancer, Centre for Medical Oncology, Barts and the London School of Medicine, University of London, London, United Kingdom
    J Clin Invest 118:2427-37. 2008
    ....
  30. ncbi Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
    Peter C Taylor
    The Kennedy Institute Division, Faculty of Medicine, Imperial College School of Medicine, 65 Aspenlea Road, London W6 8LH, United Kingdom
    Curr Opin Pharmacol 10:308-15. 2010
    ..The mode of administration of each agent, clearance and the local tissue concentrations achieved may also confer unique characteristics of relevance with respect to efficacy and safety...
  31. ncbi How I treat autoimmune hemolytic anemias in adults
    Klaus Lechner
    Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Blood 116:1831-8. 2010
    ..They may be treated in a way similar to primary autoimmune hemolytic anemias, by immunosuppressants or by treatment of the underlying disease...
  32. ncbi Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis
    Gangjun Du
    Protein and Peptide Pharmaceutical Laboratory, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
    Cancer Res 69:3205-12. 2009
    ..Naringenin could be an ideal therapeutic agent in the treatment of both cancer and fibrosis...
  33. ncbi Multiple sclerosis - established and novel therapeutic approaches
    Rainer Ehling
    Clinical Department of Neurology, Innsbruck Medical University, Austria
    Cent Nerv Syst Agents Med Chem 10:3-15. 2010
    ..This will pave the way for an optimized treatment approach, which will likely need both to target inflammation and to focus on promotion of neuroprotection and repair...
  34. ncbi Beta-interferon for multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
    Exp Cell Res 317:1301-11. 2011
    ....
  35. pmc Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis
    Chandran Ramakrishna
    Division of Virology, Beckman Research Institute, City of Hope, Duarte, California, United States of America
    PLoS Pathog 7:e1002071. 2011
    ....
  36. ncbi Inhibition of NF-κB-dependent cytokine and inducible nitric oxide synthesis by the macrocyclic ellagitannin oenothein B in TLR-stimulated RAW 264.7 macrophages
    Diethart Schmid
    Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna, Austria
    J Nat Prod 75:870-5. 2012
    ..The full molecular structure of this macrocyclic ellagitannin seems to be required for its immunomodulatory actions...
  37. ncbi Effect of tick saliva on signalling pathways activated by TLR-2 ligand and Borrelia afzelii in dendritic cells
    Jaroslava Lieskovska
    Institute of Parasitology, Biology Centre of the Academy of Sciences of Czech Republic, Ceske Budejovice, Czech Republic
    Parasite Immunol 34:421-9. 2012
    ..Our cumulative data show that tick saliva interferes with several signalling pathways, thus modulating the immune functions of dendritic cells...
  38. ncbi The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study
    R K Zabad
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Mult Scler 13:517-26. 2007
    ..The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS...
  39. ncbi Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
    G Comi
    Department of Neurology, University Vita Salute and Scientific Institute San Raffaele, Milan, Italy
    Mult Scler 16:1360-6. 2010
    ..Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing-remitting MS (RRMS) patients...
  40. ncbi Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62
    Helen S Goodridge
    Division of Immunology, Infection, and Inflammation, University of Glasgow, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    J Immunol 174:284-93. 2005
    ....
  41. pmc The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease
    M M Harnett
    Division of Immunology, Infection and Inflammation, Glasgow Biomedical Centre, University of Glasgow, Glasgow, UK
    Clin Exp Immunol 159:256-67. 2010
    ....
  42. ncbi Disease-modifying agents for multiple sclerosis: recent advances and future prospects
    Til Menge
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Drugs 68:2445-68. 2008
    ..Finally, with the advent of these highly potent novel therapies, rare, but potentially serious adverse effects have been noted, namely infections and malignancies. These are critically reviewed and put into perspective...
  43. pmc Immunological mechanisms of pentoxifylline in chronic heart failure
    Steven M Shaw
    The Transplant Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester M23 9LT, UK
    Eur J Heart Fail 11:113-8. 2009
    ..This review article provides an insight into the potential beneficial mode of the action of PTX in CHF and calls for more investigation of this interesting agent...
  44. ncbi Streptochlorin, a marine natural product, inhibits NF-kappaB activation and suppresses angiogenesis in vitro
    In Kwon Choi
    Chemical Genomics Laboratory, Department of Biotechnology, College of Engineering, Yonsei University, Seoul 120 749, Korea
    J Microbiol Biotechnol 17:1338-43. 2007
    ..These data demonstrate that streptochlorin is a new inhibitor of NF-kappaB activation and can be a basis for the development of novel anti-angiogenic agents...
  45. ncbi Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura
    T Robak
    Department of Hematology, Medical University of Lodz, 2, Ciolkowskiego str, Lodz 93 510, Poland
    Hematology 14:227-36. 2009
    ..Thus, in patients with chronic ITP, a two-day regimen of Privigen was effective in increasing platelet count, reducing bleeding events and was well tolerated...
  46. ncbi Neuropsychological sequelae of non-central nervous system cancer and cancer therapy
    Jeffrey S Wefel
    Department of Neuro Oncology, Section of Neuropsychology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX 77030 4009, USA
    Neuropsychol Rev 18:121-31. 2008
    ....
  47. ncbi The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis
    M M Harnett
    Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK
    Ann Rheum Dis 67:518-23. 2008
    ..As a first step to developing ES-62-based drugs, the aim of this study was to determine whether the PC-moiety of ES-62 was responsible for its anti-inflammatory actions...
  48. ncbi Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature
    Giuseppe Cianchini
    Division of Dermatology, Istituto Dermopatico dell Immacolata, IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy
    Arch Dermatol 143:1033-8. 2007
    ..We report 10 cases of pemphigus vulgaris and 2 cases of pemphigus foliaceous treated with rituximab--to our knowledge the largest series of patients so far--and review the existing literature on the topic...
  49. ncbi The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    V Devonshire
    University of British Columbia Hospital MS Clinic, Canada
    Eur J Neurol 18:69-77. 2011
    ..This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing-remitting MS...
  50. ncbi Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
    Hiangkiat Tan
    HealthCore, Inc, 800 Delaware Ave, Wilmington, DE 19801, USA
    Adv Ther 28:51-61. 2011
    ..However, only limited data currently exist on the impact of treatment adherence on MS-related clinical and economic outcomes in the real world setting...
  51. pmc Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
    Anne H Cross
    Box 8111, Department of Neurology, Washington University School of Medicine, 660 S Euclid Avenue, Saint Louis, MO 63110, USA
    J Neuroimmunol 180:63-70. 2006
    ..In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well...
  52. ncbi Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
    Ruth Pepper
    Imperial College Kidney and Transplant Institute, West London Renal and Transplant Centre, Hammersmith Hospital, London UK
    Nephrol Dial Transplant 24:3717-23. 2009
    ..We then attempted steroid reduction/withdrawal...
  53. ncbi Immunomodulation by intravenous immunoglobulin: role of regulatory T cells
    Mohan S Maddur
    Unite 872, Institut National de la Santé et de la Recherche Médicale Paris, Paris, France
    J Clin Immunol 30:S4-8. 2010
    ..However, the molecular mechanisms involved in IVIG-mediated modulation of Tregs are unclear and need further investigation...
  54. ncbi MgC1q, a novel C1q-domain-containing protein involved in the immune response of Mytilus galloprovincialis
    Camino Gestal
    Instituto de Investigaciones Marinas CSIC, Eduardo Cabello 6, 36208 Vigo, Spain
    Dev Comp Immunol 34:926-34. 2010
    ..The high sequence variability suggests that somatic diversification of these nonself recognition molecules could have occurred...
  55. ncbi Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo
    George Hajishengallis
    Division of Oral Health and Systemic Disease Department of Periodontics, University of Louisville Health Sciences Center, Louisville, KY 40292, USA
    J Immunol 179:2359-67. 2007
    ..Therefore, CR3 blockade may represent a promising immunomodulatory approach for controlling human periodontitis and possibly associated systemic diseases...
  56. ncbi Heat shock protein 60: specific binding of lipopolysaccharide
    Christiane Habich
    German Diabetes Clinic, German Diabetes Center, Leibniz Institute, Heinrich Heine University, Dusseldorf, Germany
    J Immunol 174:1298-305. 2005
    ..Our studies identified a defined region of HSP60 involved in LPS binding, thereby implicating a physiological role of human HSP60 as LPS-binding protein...
  57. ncbi Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study
    F Patti
    Department of Neurosciences, University of Catania, Catania, Italy
    Mult Scler 15:779-88. 2009
    ..Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing-remitting (RR) MS is unclear...
  58. ncbi The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells
    Dimitrios Mougiakakos
    Karolinska University Hospital Huddinge, Stockholm, Sweden
    Blood 117:4826-35. 2011
    ....
  59. pmc Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma
    Darryl A Oble
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Warren 827, Boston, MA 02114, USA
    Cancer Immun 9:3. 2009
    ..Therefore, considerable research is needed to better elucidate the function and prognostic significance of TILs in both untreated melanoma and tumors treated with "biological" therapy...
  60. ncbi Beyond the increasing complexity of the immunomodulatory HLA-G molecule
    Edgardo D Carosella
    CEA, IBM, Service de Recherches en Hemato Immunologie, Paris, France
    Blood 111:4862-70. 2008
    ..We highlight here what we consider are recent key basic findings on the immunomodulatory function of HLA-G. These strengthen the case for considering HLA-G as clinically relevant...
  61. ncbi Immunomodulatory properties of mesenchymal stromal cells
    Alma J Nauta
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Blood 110:3499-506. 2007
    ....
  62. pmc Evidence that cytokines play a role in rheumatoid arthritis
    Fionula M Brennan
    Kennedy Institute of Rheumatology, Imperial College London, London, UK
    J Clin Invest 118:3537-45. 2008
    ..In this Review, we discuss the biologic contribution and therapeutic potential of the major cytokine families to RA pathology, focusing on molecules contained within the TNF-alpha, IL-1, IL-6, IL-23, and IL-2 families...
  63. pmc Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
    Gertie J Oostingh
    Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria
    Part Fibre Toxicol 8:8. 2011
    ..However, before assays can be standardised, it is important that suitable methods are established and validated...
  64. ncbi The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
    Michael Hutchinson
    Dept of Neurology, St Vincent s University Hospital, Dublin, Ireland
    J Neurol 256:405-15. 2009
    ..These results indicate that natalizumab is effective in reducing disability progression and relapses in patients with relapsing MS, particularly in patients with highly active disease...
  65. ncbi Mechanism of action of mitoxantrone
    Edward J Fox
    MS Clinic of Central Texas, 7200 Wyoming Springs Dr, Suite 1100, Round Rock, TX 78681, USA
    Neurology 63:S15-8. 2004
    ..Finally, it inhibits macrophage-mediated myelin degradation. Compared with interferon betas, mitoxantrone has a broad range of actions and has effects on many different types of immune cells...
  66. ncbi Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1
    Kuo I Lin
    Genomics Research Center, Academia Sinica, Taipei 115, Taiwan
    J Biol Chem 281:24111-23. 2006
    ..These results establish the signaling and molecular mechanisms of Reishi-F3 on promoting antibody secretion...
  67. pmc Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome
    Catherine Melander
    Department of Nephrology, Assistance Publique Hôpitaux Paris, Universite Paris Descartes, Hopital Necker, Paris, France
    Clin J Am Soc Nephrol 4:579-87. 2009
    ..Rituximab, a monoclonal chimeric anti-B cell antibody, is increasingly used in patients with lupus nephritis, but reported series were small and had a short follow-up...
  68. ncbi Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond
    M Mohty
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Leukemia 21:1387-94. 2007
    ....
  69. ncbi T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta
    Luca Durelli
    Department of Clinical and Biological Sciences, Division of Neurology, San Luigi Gonzaga School of Medicine, Orbassano Torino, Turin, Italy
    Ann Neurol 65:499-509. 2009
    ..We characterized the Th1/Th17 cell populations in peripheral blood (PB), their interferon (IFN) receptor expression sensitivity to IFN-beta in MS patients...
  70. ncbi Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression
    M Krakauer
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Copenhagen, Denmark
    Mult Scler 14:622-30. 2008
    ..We studied patterns of in vivo blood mononuclear cell (MNC) and whole blood cytokine and transcription factor mRNA expression before and during IFN-beta therapy in MS...
  71. ncbi ES-62, a filarial nematode-derived immunomodulator with anti-inflammatory potential
    William Harnett
    Department of Immunology, University of Strathclyde, 27 Taylor Street, Glasgow G4 0NR, UK
    Immunol Lett 94:27-33. 2004
    ..The nematode product was also able to suppress pro-inflammatory cytokine release in vitro in synovial cells derived from RA patients. ES-62 thus constitutes a pathogen-derived immunomodulator with significant therapeutic potential...
  72. ncbi Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
    Bang Ning Lee
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:3999-4008. 2011
    ..Lenalidomide, an immunomodulatory agent, has activity in lymphoproliferative disorders. The authors, therefore, evaluated its effects on T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (CLL)...
  73. ncbi Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
    Frank Waldron-Lynch
    Department of Immunobiology, Yale University School of Medicine, 300 George Street, Suite 353, New Haven, Connecticut 06511, USA
    Nat Rev Drug Discov 10:439-52. 2011
    ..We also discuss next-generation combination immunotherapies that may be administered as adjuvant therapy at time of diagnosis...
  74. ncbi Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
    Norman Latov
    Peripheral Neuropathy Center, Cornell University, New York, New York 10021, USA
    Arch Neurol 67:802-7. 2010
    ..To investigate the timing, course, and clinical characteristics of the response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)...
  75. ncbi Distinct immunomodulatory properties of Lactobacillus paracasei strains
    R D'Arienzo
    Institute of Food Sciences, National Research Council CNR, Avellino, Italy
    J Appl Microbiol 111:1482-91. 2011
    ..This study was performed to ascertain the immunomodulatory effect of Lactobacillus paracasei strains. These strains were also genetically characterized...
  76. ncbi Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
    Harald Hegen
    Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mult Scler 18:610-5. 2012
    ..Neutralizing antibodies (NAbs) affect the efficacy of interferon-beta (IFNβ) treatment in multiple sclerosis (MS) patients, particularly if NAbs persist. Persistency depends on NAb titers, which differ between IFNβ preparations...
  77. ncbi Interferon-α therapy in noninfectious uveitis
    Christoph Deuter
    Centre for Ophthalmology, University of Tubingen, Tubingen, Germany
    Dev Ophthalmol 51:90-7. 2012
    ..This chapter updates the mechanisms and pharmacology of IFN and its effects in experimental studies. This is followed by a summary of clinical studies in intraocular inflammation and the spectrum of side effects...
  78. ncbi Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis
    Marc Weidenbusch
    Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universitat Munchen, Munich, Germany
    Nephrol Dial Transplant 28:106-11. 2013
    ..At present, no such trial is available for the use of RTX in refractory LN...
  79. pmc Novel immunomodulators from hard ticks selectively reprogramme human dendritic cell responses
    Stephen G Preston
    Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS Pathog 9:e1003450. 2013
    ..Our results suggest a previously unknown mechanism for parasite-induced subversion of adaptive immunity, one which may also facilitate pathogen transmission. ..
  80. pmc Immunomodulatory beta-glucan from Lentinus edodes activates mitogen-activated protein kinases and nuclear factor-kappaB in murine RAW 264.7 macrophages
    Xiaojuan Xu
    Department of Chemistry, Wuhan University, Wuhan 430072, China
    J Biol Chem 286:31194-8. 2011
    ..These data demonstrate that LNT-S glucan carries out its immunomodulating activity by activating MAPK signaling pathways without secretion of TNF-α and NO...
  81. ncbi Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury
    Martin Urner
    Institute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland
    Am J Respir Cell Mol Biol 45:617-24. 2011
    ....
  82. ncbi Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma
    Antonia Busse
    Department of Medicine III Hematology and Oncology, Charite, Campus Benjamin Franklin, Berlin, Germany
    Eur J Cancer 47:690-6. 2011
    ..Therefore, we asked whether sorafenib had an influence on peripheral immune effector cells in a cohort of 35 mRCC patients receiving sorafenib treatment...
  83. ncbi Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis
    Michael S Krathen
    Department of Dermatology, Tufts Medical Center, 800 Washington Street, Box 114, Boston, MA 02111, USA
    J Rheumatol 37:2205-15. 2010
    ..The purpose of this study is to evaluate and summarize the available data pertinent to this question...
  84. pmc Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
    Yannick Bulliard
    Department of Oncology and 2 Laboratory Animal Services, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA
    J Exp Med 210:1685-93. 2013
    ..These findings may have broad implications for antibody engineering efforts aimed at enhancing the therapeutic activity of immunomodulatory antibodies. ..
  85. ncbi Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study
    Andrew R Pachner
    UMDNJ New Jersey Medical School, 185 South Orange Ave, MSBH506, Newark, NJ 07103, USA
    Neurology 73:1493-500. 2009
    ....
  86. pmc Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides
    Per Björk
    Active Biotech AB, Lund, Sweden
    PLoS Biol 7:e97. 2009
    ..The specific binding of quinoline-3-carboxamides to S100A9 explains the immunomodulatory activity of this class of compounds and defines S100A9 as a novel target for treatment of human autoimmune diseases...
  87. ncbi Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury
    G Tiegs
    Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen Nuremberg, Erlangen, Germany
    Z Gastroenterol 45:63-70. 2007
    ....
  88. pmc Ixodes scapularis saliva mitigates inflammatory cytokine secretion during Anaplasma phagocytophilum stimulation of immune cells
    Gang Chen
    Center for Disease Vector Research and Department of Entomology, University of California Riverside, Riverside, CA 92521, USA
    Parasit Vectors 5:229. 2012
    ..However, how I. scapularis saliva influences host cytokine secretion in the presence of the obligate intracellular rickettsial pathogen Anaplasma phagocytophilum remains elusive...
  89. ncbi Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients
    Giovanni D'Arena
    Hematology and Stem Cell Transplantation Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Eur J Haematol 85:502-7. 2010
    ..There are no standard therapies for chronic lymphocytic leukemia (CLL)-associated immune thrombocytopenia (IT) so far...
  90. ncbi Role of rituximab therapy in glomerulonephritis
    David Jayne
    Renal Medicine, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Am Soc Nephrol 21:14-7. 2010
    ..The toxicity and infective risk of B cell-targeted agents in renal disease needs to be determined as well as their optimal dosing in combination with conventional agents...
  91. ncbi Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis
    Andrea Mencarelli
    Dipartimento di Medicina Clinica e Sperimentale, University of Perugia, Italy
    Eur J Pharmacol 665:29-39. 2011
    ..This study suggests the exploitation of non-antibiotic macrolides in the treatment of inflammatory disorders characterized by immune dysfunction...
  92. ncbi Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression
    Nadine Pigard
    BMT Research GmbH, Vienna, Austria
    J Neuroimmunol 209:114-20. 2009
    ..We suggest that the modulation of chemokine expression in peripheral T cells contributes to the beneficial activity of IVIG in patients with MS exacerbation...
  93. ncbi Mechanisms of probiotic actions - A review
    Tobias A Oelschlaeger
    Institut für Molekulare Infektionsbiologie, University of Wurzburg, Rontgenring 11, D 97070 Wurzburg, Germany
    Int J Med Microbiol 300:57-62. 2010
    ..The individual combination of such properties in a certain probiotic strain determines its specific probiotic action and as a consequence its effective application for the prevention and/or treatment of a certain disease...
  94. ncbi Monoclonal antibodies in MS: mechanisms of action
    Bibiana Bielekova
    Neuroimmunological Diseases Unit, National Institute NIH, Bethesda, MD 20892, USA
    Neurology 74:S31-40. 2010
    ....
  95. ncbi Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus
    G W Tew
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080 4990, USA
    Lupus 19:146-57. 2010
    ..Together, these findings demonstrate clear biologic activity of RTX in subsets of SLE patients, despite an overall lack of incremental clinical benefit with RTX in the EXPLORER trial...
  96. ncbi Structural studies of a peptide with immune modulating and direct antimicrobial activity
    Michal Wieczorek
    Chemistry Department, University of British Columbia, Vancouver, BC, Canada
    Chem Biol 17:970-80. 2010
    ..The structural data are discussed in light of the ability of 1018 to potently induce chemokine responses, suppress the LPS-induced TNF-α response, and directly kill both Gram-positive and Gram-negative bacteria...
  97. pmc Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium
    Igor A Schepetkin
    Departments of Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA
    J Immunol 183:6754-66. 2009
    ..The ability of oenothein B to modulate phagocyte functions in vitro and in vivo suggests that this compound is responsible for at least part of the therapeutic properties of E. angustifolium extracts...
  98. ncbi Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action
    Masaharu Shinkai
    Ministry of Defense and National Defense Medical College, Japan
    Pharmacol Ther 117:393-405. 2008
    ..Consistent with this, macrolide antibiotics possibly reduce mucin production as well as neutrophil migration by interfering with ERK signal transduction...
  99. ncbi Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?
    Aryeh M Abeles
    New York University School of Medicine, The Hospital for Joint Diseases, New York, New York, USA
    Arthritis Rheum 54:393-407. 2006
  100. ncbi Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
    Chris H Polman
    Department of Neurology, MS Center Amsterdam, Free University Medical Center, Amsterdam, Netherlands
    Lancet Neurol 9:740-50. 2010
    ..In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity...
  101. ncbi Tick saliva suppresses IFN signalling in dendritic cells upon Borrelia afzelii infection
    J Lieskovska
    Biology Center of the Czech Academy of Sciences, Institute of Parasitology, Ceske Budejovice, Czech Republic
    Parasite Immunol 34:32-9. 2012
    ..Our data indicate that I. ricinus tick saliva may modulate the host immune response by attenuating the initial signal transduction pathway of type I IFN...

Research Grants62

  1. Progression of Autoimmunity During Puberty in SLE
    KATHLEEN M O'NEIL; Fiscal Year: 2011
    ..understand the causes of sex differences in autoimmunity in general, and SLE in specific, we will measure immunologic factors important in lupus pathogenesis, and will correlate changes in these immunologic parameters with pubertal ..
  2. Adiposity and Outcomes of Clinically Localized Prostate Cancer
    Vincent L Freeman; Fiscal Year: 2013
    ..The overall hypothesis is that excess adiposity alters prostatic exposure to nutritional, hormonal, and immunologic factors influenced by weight status and implicated in prostate cancer progression, and that inter- individual ..
  3. Gender Factors Influencing Susceptability to Influenza
    Sabra L Klein; Fiscal Year: 2010
    ....
  4. Melanoma Prevention: Using the Sun
    Marianne Berwick; Fiscal Year: 2013
    ..The NCI clearly states that prevention must be based on knowledge developed by integrative population science teams working in the population and in the laboratory. ..
  5. Immunological Factors and Risk of Vulvodynia
    Bernard L Harlow; Fiscal Year: 2013
    ..It will also help determine what factors contribute toward successful recruitment of subjects for important studies of stigmatizing conditions which can be extremely prevalent among women. ..
  6. A novel strategy in antimicrobial drug discovery against Porphyromonas gingivalis
    VICTORIA NANETTE STONE; Fiscal Year: 2013
    ..gingivalis, potentially demonstrating drugability and selectivity within a poly-microbial environment. Once completed, our study may give insight into a novel therapeutic approach when dealing with periodontal disease. ..
  7. INNATE/ADAPTIVE IMMUNE RESPONSE TO SALMONELLA TYPHIMURIUM
    MUYIWA EMMANUEL AWONIYI; Fiscal Year: 2010
    ..Our studies seek to provide new insights into the immune mechanisms that protect against NTS, identify differences that contribute to greater vulnerability, and suggest strategies by which to overcome this vulnerability. ..
  8. Mechanisms of Immune Evasion and Recognition in Human Syphilis
    ADRIANA RAQUEL CRUZ; Fiscal Year: 2013
    ..which exhibits both poor cytolytic activity and impaired cytokine production suggests that additional immunologic factors play a role in the duality of the immune response to Tp...
  9. Innate Immunogenetics &Human Infections
    Thomas R Hawn; Fiscal Year: 2013
    ..Over the past 10 years, my research goals have been to understand the genetic and immunologic factors that influence human susceptibility to infections such as tuberculosis and to use this knowledge to design ..
  10. Risk and Protective Factors for Immune Health in Pediatric Cancer
    MARCIA WINTER; Fiscal Year: 2013
    ..g., coping, meaning making) interact to influence mental health and immunologic factors in turn influences disease processes (e.g., progression, recovery, quality of life)...
  11. Role of Chlamydia Species in Preterm Birth and Placental Dysfunction
    Robin R Ingalls; Fiscal Year: 2013
    ..Placental inflammation secondary to infectious or immunologic factors is believed to be one of the risk factors for preterm labor...
  12. Genetic Determinants of Mucosal Defense to Salmonella Infection
    Kelly D Smith; Fiscal Year: 2010
    ....
  13. Seminal HIV-1 Shedding and Drug Resistance in HIV-1/HSV-2 Coinfected Men on HAART
    Deborah Anderson; Fiscal Year: 2009
    ..abstract_text> ..
  14. A Chicken Model to Study Hepatitis E Virus Pathogenesis
    Xiang Jin Meng; Fiscal Year: 2013
    ..The results will be important for devising effective prevention and treatment strategies against HEV. ..
  15. Infection and Inflammation in Adult Gliomas
    Michael E Scheurer; Fiscal Year: 2012
    ..My research proposal will focus on examining viral and immunologic factors in glioma risk and patient outcome...
  16. Syphilis: Translating technology to understand a neglected epidemic
    Carlos F Caceres; Fiscal Year: 2013
    ....
  17. Analysis of beta cell death in Type 1 diabetes
    Kevan C Herold; Fiscal Year: 2013
    ..This notion is supported by the observation that non-immunologic factors such as age and glucose control modify the responses to immune therapies and the kinetics of [unreadable] ..
  18. Pathway analysis of tuberculosis pathogenesis
    CATHERINE MARIE STEIN; Fiscal Year: 2013
    ..Previous studies have shown a role for both genetic and immunologic factors that predispose to progression from Mtb infection to active TB disease, but these factors have not been ..
  19. Parainfluenza Virus Infection in Hematopoietic Cell Transplant Recipients
    ANGELA JEAN PECK CAMPBELL; Fiscal Year: 2012
    ..proposal is that asymptomatic, or subclinical, PIV shedding in HCT recipients is common, related to host immunologic factors, and may increase PIV transmission to others...
  20. Coordinating Center for the Pediatric HIV/AIDS Cohort Study II
    RUSSELL BARRETT VAN DYKE; Fiscal Year: 2013
    ..3) to study genetic, epigenetic, virologic (including antiretroviral resistance), and immunologic factors which impact the course of HIV infection, its complications and response to treatment...
  21. Genetic factors influencing the immune response to carcinomas in skin cancer
    KYLE DAVID HALLIWILL; Fiscal Year: 2013
    ....
  22. Clinical Development of Hu14.18-IL2 Targeted Therapy
    Paul M Sondel; Fiscal Year: 2013
    ..18-IL2: Blood and tumor specimens from treated pts will be tested for biologic and immunologic factors to help clarify the mechanisms of antitumor effects and of toxicity. 3. Increase antitumor efficacy of hu14...
  23. Biomarkers of spontaneous acute hepatitis C virus resolution
    Suganya Selvarajah; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): In the proposed study we will investigate soluble immunologic factors present in serum following transfusion transmission through the course of acute HCV infection to identify biomarkers influencing ..
  24. R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines
    CECILIA C CHENG-MAYER; Fiscal Year: 2013
    ..We posit that such studies may lead to the identification of biologic and/or immunologic factors that impact HIV-1 subtype spread and disease.
  25. NOVEL EVALUATION OF LACTATION PERFORMANCE
    Cutberto Garza; Fiscal Year: 1991
    ..Specific aims are to determine if selected milk immunologic factors are absorbed by the infant or if endogenous production is stimulated and to assess endogenous losses of ..
  26. REGULATION OF MHC GENES IN TROPHOBLAST
    DOUGLAS ANTCZAK; Fiscal Year: 1999
    ..Our proposed studies of equine pregnancy are, therefore, likely to shed light on mechanisms that operate in human pregnancy. They may also have relevance to MHC gene regulation in tumor growth and transplantation biology. ..
  27. Mechanisms and Consequences of Immune Activation in HIV Infected Children
    Alka Khaitan; Fiscal Year: 2013
    ..We will examine novel T cell subsets, Th17 and T regulatory cells, and immunologic factors affecting activation that are largely unexplored in HIV infected children...
  28. Breast milk: Physiology, Biochemistry and Outcomes
    Ardythe Morrow; Fiscal Year: 2006
    ..health; 3) Discuss expression of endogenous and exogenous factors in human milk, including nutrients, immunologic factors, toxins, drugs, and other factors and the genetic regulation of such expression In September 2006, the ..
  29. INFECTION IN ELBW INFANTS:PROTECTION WITH MOTHER'S MILK
    Nancy Rodriguez; Fiscal Year: 2005
    ..Selected immunologic factors, such as secretory immunoglobulin A, are absorbed and excreted in the infant's urine; lactoferrin, with ..
  30. Psychoneuroimmunology of T Cell Activation
    Steve Zalcman; Fiscal Year: 2004
    ..abstract_text> ..
  31. CAPSULAR POLYSACCHARIDES AND ENTEROCOCCAL INFECTIONS
    Johannes Huebner; Fiscal Year: 2002
    ..applicant's abstract): The long-term goal of this study is to understand the molecular, biochemical, and immunologic factors that contribute to the pathogenesis of Enterococcus faecalis and E...
  32. Role of Enterococcal Polysaccharides in Virulence
    Johannes Huebner; Fiscal Year: 2006
    ..provided by applicant): The long-term goal of this study is to understand the molecular, biochemical, and immunologic factors that contribute to the pathogenesis of Enterococcus faecalis and Enterococcus faecium infections...
  33. Vascular Remodeling in Transplant Arteriosclerosis
    Christiane Ferran; Fiscal Year: 2009
    ..The causes of chronic rejection and TAV are likely multifactorial including immunologic and non- immunologic factors that integrate at the level of the vascular wall leading to a phenotypic switch of endothelial (EC) and ..
  34. PSYCHOSOCIAL, BEHAVIOR AND IMMUNE FACTORS IN BACK PAIN
    Eric Hurwitz; Fiscal Year: 2004
    ....
  35. GENETIC, BIOLOGIC, & IMMUNOLOGIC DETERMINANTS OF ASTHMA
    Mario Castro; Fiscal Year: 2006
    ..this application will lead to a better understanding of the interaction of genetic, biologic, and immunologic factors following serious RSV infection which lead to the development of asthma in early life...
  36. BEHAVIORAL AND IMMUNOLOGICAL FACTORS IN CORONARY DISEASE
    Willem Kop; Fiscal Year: 2005
    ....
  37. Immunologic Factors In Progressive Autoimmune Disease
    ROBERT FUJINAMI; Fiscal Year: 2005
    ..These new models could help explain the transition from RR disease to progressive disease often observed in MS patients. ..
  38. T Cell Cytokines and Renal Allograft Survival
    Kevin Mange; Fiscal Year: 2003
    ..Understanding the genetic and immunologic factors that are associated with the risks of foreshortened allograft survival or acute rejection may allow a ..
  39. 2002 Levine Symposium- Advances in Islet Cell Biology
    Fouad Kandeel; Fiscal Year: 2002
    ..sessions dedicated to the following: Functional Development and Regulation of Beta Cells, Genetic and Immunologic Factors in Beta Cell Function, Islet Cell Signaling Network and Functional Response, Beta Cell Differentiation, ..
  40. SFSTDS CRC
    Nancy Padian; Fiscal Year: 2002
    ..2. Identify immunologic factors associated with initial human papillomavirus (HPV) infection and identify host factors predictive of ..
  41. Mechanisms of Radiation Induced Fatigue in Cancer
    Julienne Bower; Fiscal Year: 2006
    ..Together with a targeted program of didactic instruction, this project will prepare the candidate to become a fully independent behavioral scientist in the field of cancer prevention and control research. ..
  42. CELL PHENOTYPE AS A SURROGATE MARKER IN PEDIATRIC AIDS
    Susan Plaeger; Fiscal Year: 1990
    ..There is difficulty in extrapolating findings obtained in adults to children due to immunologic factors peculiar to the pediatric population...
  43. IMMUNOGENETICS OF HUMAN DIABETES
    Ake Lernmark; Fiscal Year: 2007
    ..The long term objective is to identify novel approaches to prevention and cure of type 1 diabetes. ..
  44. LYSOZYME SECRETION AND PANETH CELL FUNCTION
    Stanley Erlandsen; Fiscal Year: 1980
    ..the in vitro endocytic activity of isolated Paneth cells and the immunologic factors influencing their phagocytosis of recognizable tracers...
  45. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines ..
  46. MECHANISMS IN SUCCESSFUL THERAPY OF GVHD WITH MOAB
    ROBERT TRUITT; Fiscal Year: 2001
    ..Mechanistic insights gained from the studies, together with the biological principles identified, will facilitate the translational application of MoAb to clinical BMT. ..
  47. The dynamics of granuloma formation in tuberculosis
    Denise Kirschner; Fiscal Year: 2005
    ..The ability to synthesize the data generated by the experiments in the models allows for an understanding of the dynamics of granuloma formation as more than the sum of its parts. ..
  48. CHRONIC INTESTINAL INFLAMMATION--MECHANISMS AND EFFECTS
    CHARLES ELSON; Fiscal Year: 2003
    ..appears to be multi-factorial and particularly involve complex interactions among genetic environmental and immunologic factors. The scientific fields of immunology and genetics are thought to most likely hold the answer to the puzzle ..
  49. PSYCHOLOGICAL INFLUENCES ON IMMUNE RESPONSES TO HPV
    Carolyn Fang; Fiscal Year: 2001
    ..However, the influence of psychosocial, behavioral and immunologic factors on cancer risk and development needs further exploration...
  50. DISTRESS AND IMMUNE FUNCTION IN CERVICAL DYSPLASIA
    Carolyn Fang; Fiscal Year: 2003
    ..abstract_text> ..
  51. IMMUNOREGULATION IN ASYMPTOMATIC HIV-INFECTED PEOPLE
    Dorothy Lewis; Fiscal Year: 1990
    ..The final goal is to determine whether T8+Leu7+ expansion in ARC patients is significant in the progression of ARC to AIDS...
  52. CAPILLARY ELECTROPHORESIS AND MASS SPECTROMETRY
    Terry Lee; Fiscal Year: 1990
    ..Work will be directed toward the analysis of peptides and proteins but advances can be readily applied to other compound classes...
  53. NINTH INTERNATIONAL SYMPOSIUM ON CELIAC DISEASE
    Alessio Fasano; Fiscal Year: 2000
    ....
  54. Chemokine Dynamics in the HIV-1/SIV Infected Lung
    Denise Kirschner; Fiscal Year: 2006
    ..End of Abstract) [unreadable] [unreadable]..
  55. CELLULAR IMMUNE FACTORS IN VERTICAL TRANSMISSION OF HIV
    Christel Uittenbogaart; Fiscal Year: 2000
    DESCRIPTION: This is a 4 year competitive renewal which proposes to identify immunologic factors that influence the pathogenesis of HIV disease during pregnancy and are associated with vertical transmission of HIV infection...
  56. Cell Mediated Immunity in HIV Infected Children
    Douglas Nixon; Fiscal Year: 2004
    ..The goal of this grant application is to better understand immunopathogenic factors relevant to HIV infected children so they can be better placed to take advantage of developments in vaccines and new treatments. ..
  57. Cell Mediated Immunity in HIV Infected Children
    Douglas Nixon; Fiscal Year: 2009
    ..The goal of this grant application is to better understand immunopathogenic factors relevant to HIV infected children so they can be better placed to take advantage of developments in vaccines and new treatments. ..
  58. Placental Immunopathology in the FIV-infected Cat Model
    KAREN COATS; Fiscal Year: 2006
    ..The production of immunomodulators will be examined in infected and uninfected pregnant cats. We hope to identify immune parameters promoting in utero viral transmission and fetal damage. [unreadable] [unreadable]..
  59. THE EFFECTIVENESS OF INFLUENZA VACCINATION
    Paul Hebert; Fiscal Year: 1999
    ..Do health care market factor-such as reduced hospital censuses and" managed care "spill-over" effect-help explain the paradoxical increase in P&l hospitalizations? ..
  60. HIV INFECTION/IMMUNITY IN THE FEMALE REPRODUCTIVE TRACT
    ALEXANDRIA HOWELL; Fiscal Year: 2003
    ..Data from these studies will increase our understanding of potential viral and immunologic factors that affect the heterosexual acquisition of HIV-1 infection by women, will be useful in developing ..
  61. Mentored Patient-Oriented Research Career Development Aw
    ASHER SCHACHTER; Fiscal Year: 2004
    ..These studies may provide insight and guidance for the development of markers of steroid resistance as well as novel therapies for SRNS. ..
  62. LYMPHOCYTE FUNCTION IN RECURRENT APHTHOUS ULCERATION
    John Greenspan; Fiscal Year: 1980
    ..A PHA dose-response assay with RAU patients' lymphocytes will be used to measure the presence and extent of this T-cell dysfunction...